Since BFOV has demonstrated anti-diabetic and insulin-sensitizing activities in diabetic rats, it should be regarded as a new orally active anti-diabetic organic vanadium complex that may be considered as a promising new therapeutic agent for T2DM treatment [74]. The gene discussed is INS; the disease is type 2 diabetes mellitus.